Galunisertib

Description	LY2157299 potently inhibits the TGFβ receptor signaling. LY2157299 abolishes the TGFβ induced Smad2 phosphorylation in HUVEC cells. LY2157299 also shows dose dependent potentiation of VEGF or bFGF induced cell proliferation in HUVEC. LY2157299 also promotes VEGF induced HUVEC cell migration. LY2157299 potentiates angiogenesis in the in vitro VEGF-stimulated cord formation assay. LY2157299 inhibits TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells in a dose-dependent manner. LY2157199 treatment stimulates hematopoiesis from primary MDS bone marrow specimens.In human glioblastoma (GBM) cells, LY2157299 treatment blocks signaling through the heteromeric TGFβ receptor complex to reduce levels of active, phosphorylated SMAD.
Pathways	TGF beta/Smad Wnt/Stem Cell
Targets	BMP/TGF beta Receptor TGF β/Smad

Cocktail of chemical compounds robustly promoting cell reprogramming protects liver against acute injury Publications Citing of Biochempartner's Galunisertib(CAS:700874-72-2)
Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells Publications Citing of Biochempartner's Galunisertib(CAS:700874-72-2)

Publications Citing of Biochempartner's Galunisertib(CAS:700874-72-2)

Publications Citing of Biochempartner's Galunisertib(CAS:700874-72-2)

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.